title: Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors:  report of 3 cases.
abstract: A wide spectrum of skin toxicities has been described in patients receiving epidermal growth factor receptor (EGFR), inhibitors, including papulopustular rash, xerosis and fissures, pruritus, mucositis, paronychia, and hair changes.Trichomegaly of the eyelashes is a rare adverse effect of EGFR inhibitor therapy and is characterized by a paradoxical overgrowth of eyelashes. We present 3 cases of trichomegaly occurred during EGFR inhibitor therapy.
authors.affiliation: Division of Clinical Dermatology, Department of Systematic Pathology, University of Naples Federico II, Napoli, Italy. gafabbro@unina.it
authors.forename: Gabriella
authors.initials: G
authors.lastname: Fabbrocini
authors.forename: Luigia
authors.initials: L
authors.lastname: Panariello
authors.forename: Sara
authors.initials: S
authors.lastname: Cacciapuoti
authors.forename: Dario
authors.initials: D
authors.lastname: Bianca
authors.forename: Fabio
authors.initials: F
authors.lastname: Ayala
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005076:Exanthema / Q000139:chemically induced; D005140:Eyelashes; D005260:Female; D006201:Hair Diseases / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D000077544:Panitumumab; D011799:Quinazolines / Q000009:adverse effects*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011799:Quinazolines; D000077544:Panitumumab; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors